Jazz Grows Rare Disease Portfolio With Gentium Buy | Chemical & Engineering News
Volume 92 Issue 1 | p. 12 | Concentrates
Issue Date: January 6, 2014

Jazz Grows Rare Disease Portfolio With Gentium Buy

Department: Business
Keywords: pharmaceuticals, biotech, rare diseases, M&A

Jazz Pharmaceuticals will pay roughly $1 billion in cash to acquire Gentium, an Italian biotech firm focused on treating rare diseases. Gentium recently received European regulatory approval for Defitelio, a treatment for a condition in which veins in the liver are blocked in people undergoing a stem cell transplant. Jazz says the purchase complements its oncology and hematology portfolio. The deal is expected to close in the first quarter.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment